Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...